...
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Long-term control of bone marrow carcinosis and severe thrombocytopenia with standard-dose chemotherapy in a breast cancer patient: a case report.
【24h】

Long-term control of bone marrow carcinosis and severe thrombocytopenia with standard-dose chemotherapy in a breast cancer patient: a case report.

机译:标准剂量化疗可长期控制乳腺癌患者的骨髓癌和严重血小板减少症:一例病例报告。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Primary metastatic breast cancer with bone marrow involvement and pronounced thrombocytopenia is rare. The myelosuppressive effect of most cytotoxic drugs limits chemotherapy in patients with cytopenia due to marrow involvement. CASE REPORT: A 62-year-old patient, who presented with locally and systemically advanced breast cancer, is reported. The initial work-up revealed bone marrow carcinosis with thrombocytopenia of less than 20,000/mm3 lung and osseous metastases without signs of suppressed erythropoiesis and leucopoiesis. The patient was stabilized with 6 different standard-dose chemotherapy regimens, antihormonal therapy, and trastuzumab before dying 57 months after first diagnosis. The patient received only platelet transfusions on 2 instances with platelets of 2,000/mm3. CONCLUSION: This case illustrates that aggressive standard chemotherapy may be feasible in selected patients with bone marrow carcinosis-associated thrombocytopenia without major bleeding episodes.
机译:背景:伴有骨髓侵犯和明显的血小板减少的原发性转移性乳腺癌很少见。大多数细胞毒性药物的骨髓抑制作用限制了由于骨髓受累而导致血细胞减少症患者的化疗。病例报告:报道了一名62岁的患者,她患有局部和全身晚期乳腺癌。最初的检查显示骨髓癌,血小板减少症少于20,000 / mm3的肺和骨转移,没有抑制红细胞生成和白细胞生成的迹象。患者在首次诊断后死亡57个月之前,通过6种不同的标准剂量化疗方案,抗激素治疗和曲妥珠单抗稳定下来。该患者在2次中仅接受了2,000 / mm3的血小板输注。结论:该病例说明,积极的标准化学疗法在选定的患有骨髓癌相关血小板减少症且无严重出血发作的患者中是可行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号